Marizyme, Inc. announced that it has recently received additional granted patents and notices of allowance for three of its core technologies in several key markets further strengthening the Company's intellectual property. Patients have recently been granted in the United States, India, South Korea, and Vietnam covering the Company's commercial product, DuraGraftT, and patent applications have additionally been allowed in Canada and Vietnam. The issued patents and allowed patent applications protect DuraGraft, a first-in-class CE marked intra-operative graft storage solution used during bypass surgeries.

DuraGraft protects vascular grafts against ischemic injury during bypass surgeries thereby reducing the incidence of complications associated with vein graft failure, leading to improved clinical outcomes. DuraGraft is the only approved product to preserve and protect vascular grafts during bypass and other vascular surgeries. The DuraGraft patent portfolio now includes granted patents and pending applications in over 30 countries throughout the world, including patents granted in the United States, Europe, Australia, India, Argentina, South Africa, Mexico, and several Asian countries, and related applications pending in the US and other countries.

Another patent application covering Marizyme's KrillaseT enzyme technology was recently allowed in Europe resulting in additional patent protection. The patents relate to mixtures of enzymes from Antarctic krill for use in the treatment of a disease related to, or an inflammatory condition caused by, a biofilm formed on a soft tissue of a mammal with the treatment including treating soft tissue with Krillase to remove or prevent formation of a biofilm. The soft tissue can be a mucosa or an epithelium of the skin.